Glaukos Corporation has completed patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. The randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center trial enrolled 275 patients across clinical sites in the United States. GLK-321 is an investigational drug candidate using Glaukos' proprietary iLution platform, a dropless transdermal delivery system applied to the outer surface of the eyelids, with physostigmine as its active pharmaceutical ingredient. The primary efficacy endpoint assesses the proportion of study eyes achieving elimination of collarettes following six weeks of treatment. Demodex blepharitis is a chronic eyelid disease associated with Demodex mite infestation, characterized by inflammation, irritation, redness, itching, and the presence of collarettes at the base of eyelashes, and is believed to be significantly underdiagnosed.
Glaukos CorpCompleted enrollment in Phase 2 study of GLK-321 for Demodex blepharitis, a positive clinical milestone.